N/A
Manufactured by Kobayashi Healthcare International, Inc.
11,295 FDA adverse event reports analyzed
Last updated: 2026-04-15
COAL TAR is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Kobayashi Healthcare International, Inc.. The most commonly reported adverse reactions for COAL TAR include PSORIASIS, MALAISE, FATIGUE, PAIN, NASOPHARYNGITIS. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for COAL TAR.
Out of 748 classified reports for COAL TAR:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 11,295 FDA FAERS reports that mention COAL TAR. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include PSORIASIS, MALAISE, FATIGUE, PAIN, NASOPHARYNGITIS, PYREXIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Kobayashi Healthcare International, Inc. in connection with COAL TAR. Always verify the specific product and NDC with your pharmacist.